BESTCILIA
Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia
| Coordinatore | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Organization address
address: SCHLOSSPLATZ 2 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙850˙875 € |
| EC contributo | 2˙993˙674 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Organization address
address: SCHLOSSPLATZ 2 contact info |
DE (MUENSTER) | coordinator | 563˙718.00 |
| 2 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 463˙950.80 |
| 3 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 393˙598.00 |
| 4 |
INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY
Organization address
address: ks. Trojdena 4 contact info |
PL (Warsaw) | participant | 261˙080.00 |
| 5 |
CYPRUS UNIVERSITY OF TECHNOLOGY
Organization address
address: ARCHBISHOP KYPRIANOS LIMASSOL SAVINGS CO OPERATIVE BANK BUILDING 3RD FLOOR 31 contact info |
CY (LIMASSOL) | participant | 259˙720.00 |
| 6 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 222˙934.80 |
| 7 |
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Organization address
address: AIRPORT DRIVE 104 SUITE 2200 CB #1350 contact info |
US (CHAPEL HILL) | participant | 213˙793.00 |
| 8 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 193˙683.00 |
| 9 |
STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
NL (AMSTERDAM) | participant | 113˙053.00 |
| 10 |
UNIVERSITY OF MIAMI
Organization address
address: ASHE BUILDING 240 contact info |
US (CORAL GABLES MIAMI) | participant | 108˙040.00 |
| 11 |
EUROPEAN RESEARCH SERVICES GMBH
Organization address
address: ROENTGENSTRASSE 19 contact info |
DE (MUENSTER) | participant | 100˙284.00 |
| 12 |
ROYAL BROMPTON AND HAREFIELD NATIONAL HEALTH SERVICE TRUST
Organization address
address: SYDNEY STREET contact info |
UK (LONDON) | participant | 99˙820.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Primary Ciliary Dyskinesia (PCD) is a rare genetically heterogeneous disorder which results from dysfunction of motile hair-like organelles (cilia) that results in severe, chronic airways disease. Due to other cilia-related disease mechanisms several other organ systems like the heart can be affected. The complexity of the disease phenotype, late diagnosis, as well as lack of evidence based management guidelines contribute to a high burden of disease and cause high health care costs. Therefore, there is a great need for observational trials as well as well-designed randomised controlled trials to put evidence-based diagnostic and treatment approaches into effect. The main objective of our project is to improve diagnosis and treatment of PCD patients. To accomplish this, we propose to: 1) Establish widespread, early diagnosis by introduction of nasal Nitric Oxide measurement as screening tool, and by introduction of high-speed videomicroscopy as diagnostic tool; 2) Develop new outcome criteria, especially a PCD-specific quality of life questionnaire, as a prerequisite for controlled PCD trials; 3) Establish a PCD registry for both cross-sectional analysis of current disease status and longitudinal observational analysis of disease progression under different regimens; 4) Generate evidence-based treatment guidelines by conducting two prospective randomized trials on the inhalation of hypertonic saline and long term azithromycin therapy. To achieve these goals members of the European Respiratory Society’s PCD task force will join forces with members of the NIH-funded US-PCD-network. In our multi-national project, we will for the first time establish evidence-based guidelines for diagnosis, clinical management and therapy. We expect that in a high proportion of children the diagnosis will be established before irreversible lung damage has occurred. In later diagnosed individuals the disease burden will be reduced and chronic respiratory failure retarded.'
Introduzione (Teaser)
Primary ciliary dyskinesia (PCD) is a rare inherited condition with symptoms including chronic lung disease, rhinosinusitis, hearing impairment and subfertility. Diagnosis is usually delayed or missed resulting in poor outcomes for such patients.